Validations Queue
106,328 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 3 of 42, 100 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
106,328
Reviewed
13
Filtered
4,152
page 3 / 42
Showing on page
100
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.65 | FDA ANDA210386: CANAGLIFLOZIN (CANAGLIFLOZIN) — AUROBINDO PHARMA LTD | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA020941: ABREVA (DOCOSANOL) — HALEON US HOLDINGS | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA BLA761309: COLUMVI (GLOFITAMAB-GXBM) — GENENTECH INC | fda 2026-06-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA208869: RUXOLITINIB (RUXOLITINIB) — APOTEX INC | fda 2026-06-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA213885: LENALIDOMIDE (LENALIDOMIDE) — EUGIA PHARMA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219271: CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE) — HETERO LABS LIMITED | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA213267: THALIDOMIDE (THALIDOMIDE) — NATCO | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA091541: LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) — MICRO LABS | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA021488: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761032: SILIQ (BRODALUMAB) — VALEANT LUXEMBOURG | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761381: OPDIVO QVANTIG (NIVOLUMAB) — BRISTOL-MYERS SQUIBB | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA200880: ACETAZOLAMIDE SODIUM (ACETAZOLAMIDE SODIUM) — MYLAN ASI | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA217497: TRETINOIN (TRETINOIN) — AMNEAL | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220043: VORICONAZOLE (VORICONAZOLE) — HAINAN POLY PHARM | fda 2026-05-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215552: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — YAOPHARMA CO LTD | fda 2026-06-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA BLA761306: EBGLYSS (LEBRIKIZUMAB-LBKZ) — ELI LILLY AND CO | fda 2026-06-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211312: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — SANDOZ | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA209956: POMALIDOMIDE (POMALIDOMIDE) — TEVA PHARMS USA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220326: VILOXAZINE HYDROCHLORIDE (VILOXAZINE HYDROCHLORIDE) — APPCO PHARMA LLC | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761468: HEPCLUDEX (BULEVIRTIDE-GMOD) — GILEAD SCIENCES INC | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA219943: KOSELUGO (SELUMETINIB) — ASTRAZENECA | fda 2026-05-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA208400: XATMEP (METHOTREXATE SODIUM) — AZURITY | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220458: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — APOTEX | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA210275: POMALIDOMIDE (POMALIDOMIDE) — MYLAN | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA205035: TRANEXAMIC ACID (TRANEXAMIC ACID) — EUGIA PHARMA | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211533: DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MSN | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211563: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA214216: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — MACLEODS PHARMS LTD | fda 2026-04-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA205402: PALIPERIDONE (PALIPERIDONE) — I3 PHARMS | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA207740: OMEPRAZOLE (OMEPRAZOLE) — DR REDDYS | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211135: RIOCIGUAT (RIOCIGUAT) — MSN | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA210215: AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) — POM PHARMA | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA202811: LINZESS (LINACLOTIDE) — ABBVIE | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA088640: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — BARR | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA214956: GABAPENTIN (GABAPENTIN) — ASCENT PHARMS INC | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA219540: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — MSN | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA072736: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA075471: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — MEITHEAL | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA218691: CEFIXIME (CEFIXIME) — FDC LTD | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219869: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — HETERO LABS LTD V | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA214056: ONAPGO (APOMORPHINE HYDROCHLORIDE) — MDD US | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761369: HYMPAVZI (MARSTACIMAB-HNCQ) — PFIZER INC | fda 2026-06-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA074521: DIPYRIDAMOLE (DIPYRIDAMOLE) — HIKMA | fda 2026-06-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA213414: DAPSONE (DAPSONE) — ALEMBIC | fda 2026-06-25 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA090170: LAMOTRIGINE (LAMOTRIGINE) — UNICHEM LABS LTD | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA072733: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA BLA761195: VYVGART (EFGARTIGIMOD ALFA) — ARGENX BV | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA217265: LENALIDOMIDE (LENALIDOMIDE) — QILU | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA209348: LENALIDOMIDE (LENALIDOMIDE) — DR REDDYS | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA206371: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — MICRO LABS | fda 2026-04-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA207974: FINGOLIMOD HYDROCHLORIDE (FINGOLIMOD HYDROCHLORIDE) — ALEMBIC | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA103792: HERCEPTIN (TRASTUZUMAB) — GENENTECH | fda 2026-05-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA216453: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ELITE LABS INC | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219395: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SPECGX LLC | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA BLA761458: EXDENSUR (DEPEMOKIMAB-ULAA) — GLAXOSMITHKLINE LLC | fda 2026-06-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA202097: FENTANYL-100 (FENTANYL) — KINDEVA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA201952: TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — MICRO LABS LTD INDIA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA218275: ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM) — ISTX | fda 2026-06-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA207037: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — ALKEM LABS LTD | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA212773: IMATINIB MESYLATE (IMATINIB MESYLATE) — EUGIA PHARMA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219408: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — SCIEGEN PHARMACEUTICALS INC | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA218897: VALSARTAN (VALSARTAN) — LAURUS | fda 2026-04-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA208055: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — TORRENT | fda 2026-04-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA063065: MINOCYCLINE HYDROCHLORIDE (MINOCYCLINE HYDROCHLORIDE) — WATSON LABS | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA217432: FAMOTIDINE (FAMOTIDINE) — LUPIN | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA218197: TRUQAP (CAPIVASERTIB) — ASTRAZENECA | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA NDA212102: FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — UCB INC | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211747: OXCARBAZEPINE (OXCARBAZEPINE) — ZYDUS | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA NDA202293: FARXIGA (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA202778: DOXYCYCLINE (DOXYCYCLINE) — STRIDES PHARMA | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA209624: BOSUTINIB (BOSUTINIB MONOHYDRATE) — MSN | fda 2026-06-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.65 | FDA ANDA219052: PERAMPANEL (PERAMPANEL) — TARO | fda 2026-06-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.64 | FDA ANDA218441: SITAGLIPTIN (SITAGLIPTIN) — BIOCON PHARMA LTD | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.64 | FDA ANDA215826: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — ZYDUS PHARMS | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA218488: EVEROLIMUS (EVEROLIMUS) — APOTEX | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.64 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.64 | FDA NDA018569: FUROSEMIDE (FUROSEMIDE) — EPIC PHARMA LLC | fda 2026-06-02 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA078316: OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — BARR LABS INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA090964: OXYMORPHONE HYDROCHLORIDE (OXYMORPHONE HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA089828: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — STRIDES PHARMA INTL | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA211825: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — UNICHEM | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA087006: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — PHARMOBEDIENT | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA211535: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — CIPLA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA219593: PREGABALIN (PREGABALIN) — UNICHEM | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA212963: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — EUGIA PHARMA | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% |